MYC and brain cancer: The PMLA as a nanoplatform allows one to covalently attach a number of anticancer moieties, e.g., antisense oligonucleotides (AONs) targeting c-Myc or EGFR/EGFRvIII, and checkpoint inhibitor antibodies such as anti-PD-1 (αPD-1), to produce a multifunctional nanomedicine against brain cancer.